Tags

Type your tag names separated by a space and hit enter

Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C.
Med Sci Monit. 2009 Apr; 15(4):CR189-93.MS

Abstract

BACKGROUND

Caspase-cleaved cytokeratin 18 (CK18-Asp396) is released from hepatocytes during apoptosis. Recent studies have indicated that serum levels of CK18-Asp396 could be a clinically useful biomarker of chronic liver disease. To shed more light on the rate of hepatocyte loss by apoptosis in chronic liver disease, serum levels of CK18-Asp396 were examined in patients with nonalcoholic steatohepatitis (NASH) and chronic hepatitis C.

MATERIAL/METHODS

Apoptotic CK18-Asp396 levels were quantified in sera from 35 patients with nonalcoholic steatohepatitis (NASH), 21 patients with chronic hepatitis C (HCV), and 18 healthy controls.

RESULTS

Analysis of serum CK18-Asp396 levels showed an increasing trend starting from healthy controls (median: 54.5 U/l), to HCV patients (80.1 U/l), to patients with NASH (144.1 U/l, Kruskall-Wallis test: P<0.001). Post hoc analyses revealed that CK18-Asp396 levels were significantly higher in the NASH patients than in both HCV patients (P=0.008) and healthy controls (P<0.001). Moreover, the levels were significantly higher in patients with HCV than in control individuals (P<0.05). In patients with chronic HCV infection there was a significant positive correlation between serum CK18-Asp396 levels and AST (r=0.442, P<0.05), the ultrasonographic grade of steatosis (r=0.446, P<0.05), and the histological steatosis score (r=0.759, P<0.001).

CONCLUSIONS

Although subject to future confirmation, these pilot findings seem to indicate that serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) are higher in patients with NASH than in those with chronic HCV infection. These data suggest that NASH patients have an increased hepatocyte loss by apoptosis compared with chronic hepatitis C patients.

Authors+Show Affiliations

Department of Internal Medicine, Uludag University Medical School, Bursa, Turkey. yusufyilmaz@uludag.edu.trNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19333204

Citation

Yilmaz, Yusuf, et al. "Elevated Serum Levels of Caspase-cleaved Cytokeratin 18 (CK18-Asp396) in Patients With Nonalcoholic Steatohepatitis and Chronic Hepatitis C." Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, vol. 15, no. 4, 2009, pp. CR189-93.
Yilmaz Y, Dolar E, Ulukaya E, et al. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. Med Sci Monit. 2009;15(4):CR189-93.
Yilmaz, Y., Dolar, E., Ulukaya, E., Akgoz, S., Keskin, M., Kiyici, M., Yerci, O., Oral, A. Y., Gul, C. B., Gurel, S., Nak, S. G., & Gulten, M. (2009). Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 15(4), CR189-93.
Yilmaz Y, et al. Elevated Serum Levels of Caspase-cleaved Cytokeratin 18 (CK18-Asp396) in Patients With Nonalcoholic Steatohepatitis and Chronic Hepatitis C. Med Sci Monit. 2009;15(4):CR189-93. PubMed PMID: 19333204.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. AU - Yilmaz,Yusuf, AU - Dolar,Enver, AU - Ulukaya,Engin, AU - Akgoz,Semra, AU - Keskin,Murat, AU - Kiyici,Murat, AU - Yerci,Omer, AU - Oral,Arzu Yilmaztepe, AU - Gul,Cuma Bulent, AU - Gurel,Selim, AU - Nak,Selim Giray, AU - Gulten,Macit, PY - 2009/4/1/entrez PY - 2009/4/1/pubmed PY - 2009/5/30/medline SP - CR189 EP - 93 JF - Medical science monitor : international medical journal of experimental and clinical research JO - Med. Sci. Monit. VL - 15 IS - 4 N2 - BACKGROUND: Caspase-cleaved cytokeratin 18 (CK18-Asp396) is released from hepatocytes during apoptosis. Recent studies have indicated that serum levels of CK18-Asp396 could be a clinically useful biomarker of chronic liver disease. To shed more light on the rate of hepatocyte loss by apoptosis in chronic liver disease, serum levels of CK18-Asp396 were examined in patients with nonalcoholic steatohepatitis (NASH) and chronic hepatitis C. MATERIAL/METHODS: Apoptotic CK18-Asp396 levels were quantified in sera from 35 patients with nonalcoholic steatohepatitis (NASH), 21 patients with chronic hepatitis C (HCV), and 18 healthy controls. RESULTS: Analysis of serum CK18-Asp396 levels showed an increasing trend starting from healthy controls (median: 54.5 U/l), to HCV patients (80.1 U/l), to patients with NASH (144.1 U/l, Kruskall-Wallis test: P<0.001). Post hoc analyses revealed that CK18-Asp396 levels were significantly higher in the NASH patients than in both HCV patients (P=0.008) and healthy controls (P<0.001). Moreover, the levels were significantly higher in patients with HCV than in control individuals (P<0.05). In patients with chronic HCV infection there was a significant positive correlation between serum CK18-Asp396 levels and AST (r=0.442, P<0.05), the ultrasonographic grade of steatosis (r=0.446, P<0.05), and the histological steatosis score (r=0.759, P<0.001). CONCLUSIONS: Although subject to future confirmation, these pilot findings seem to indicate that serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) are higher in patients with NASH than in those with chronic HCV infection. These data suggest that NASH patients have an increased hepatocyte loss by apoptosis compared with chronic hepatitis C patients. SN - 1643-3750 UR - https://www.unboundmedicine.com/medline/citation/19333204/Elevated_serum_levels_of_caspase_cleaved_cytokeratin_18__CK18_Asp396__in_patients_with_nonalcoholic_steatohepatitis_and_chronic_hepatitis_C_ L2 - https://www.medscimonit.com/download/index/idArt/869620 DB - PRIME DP - Unbound Medicine ER -